Clinical trial
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
NCT00069875 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00069875 |
|---|---|
| Title | A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer |
| Official title | Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Gemcitabine, LY293111, cisplatin |
| Enrollment | 195 |
| Start date | Sep 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Oct 6, 2003 |
| Last update posted | Dec 21, 2007 |
| Countries | Canada, Germany, Israel, Netherlands, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: